| Perwaiz Nawabi, | |
|
169 Ashley Ave Rm 202, Charleston, SC 29425-8905 | |
| (913) 669-3533 | |
| Not Available |
| Full Name | Perwaiz Nawabi |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 169 Ashley Ave Rm 202, Charleston, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639801574 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | LL87739 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Perwaiz Nawabi, 169 Ashley Ave Rm 202, Charleston, SC 29425-8905 Ph: (913) 669-3533 | Perwaiz Nawabi, 169 Ashley Ave Rm 202, Charleston, SC 29425-8905 Ph: (913) 669-3533 |
News Archive
IBM announced today that BodyMedia, Inc., a leader in wearable body monitors designed for health and wellness, is using IBM software to help consumers more easily achieve their weight-loss goals. Powered by IBM software, the new personalized feedback capabilities in the BodyMedia FIT body monitoring system now provide users with their own fitness coach.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
EKF Diagnostics, the global in vitro diagnostics business, announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking.
A new text by Kessler Foundation scientists focuses on the efficacy of cognitive rehabilitation across a variety of neurological conditions, with specific emphasis on treatment-related changes in the brain detectable via neuroimaging.
Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.
› Verified 2 days ago
Dr. Michael Charles O'laughlin, MD Surgery Medicare: Medicare Enrolled Practice Location: 169 Ashley Avenue, Room 202 Main Hospital Msc333, Charleston, SC 29425 Phone: 843-792-3072 | |
Kyler Perry, DO Surgery Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 843-792-2300 | |
Dr. Swathi Venattu, MD Surgery Medicare: Medicare Enrolled Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Antwana Sharee Wright, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Jacob Arthur Klapper, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Norman Robert Harvey, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-2123 | |
Hyejin Kwon, MD Surgery Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave, Charleston, SC 29425 Phone: 843-792-3072 |